

# Shunyao Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1282251/publications.pdf>

Version: 2024-02-01

17  
papers

918  
citations

567281

15  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1328  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pak2 Regulation of Nrf2 Serves as a Novel Signaling Nexus Linking ER Stress Response and Oxidative Stress in the Heart. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 851419.	2.4	14
2	Regulation of Long Non-coding RNAs and MicroRNAs in Heart Disease: Insight Into Mechanisms and Therapeutic Approaches. <i>Frontiers in Physiology</i> , 2020, 11, 798.	2.8	21
3	Spotlight on small molecules in cardiovascular diseases. <i>British Journal of Pharmacology</i> , 2018, 175, 1111-1113.	5.4	1
4	The p21-activated kinase 1 (Pak1) signalling pathway in cardiac disease: from mechanistic study to therapeutic exploration. <i>British Journal of Pharmacology</i> , 2018, 175, 1362-1374.	5.4	29
5	Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets. <i>British Journal of Pharmacology</i> , 2018, 175, 1293-1304.	5.4	142
6	Ginkgolide K protects the heart against endoplasmic reticulum stress injury by activating the inositol-requiring enzyme 1 $\alpha$ /X box-binding protein-1 pathway. <i>British Journal of Pharmacology</i> , 2016, 173, 2402-2418.	5.4	50
7	Smad3 Couples Pak1 With the Antihypertrophic Pathway Through the E3 Ubiquitin Ligase, Fbxo32. <i>Hypertension</i> , 2015, 66, 1176-1183.	2.7	20
8	Mkk4 Is a Negative Regulator of the Transforming Growth Factor Beta 1 Signaling Associated With Atrial Remodeling and Arrhythmogenesis With Age. <i>Journal of the American Heart Association</i> , 2014, 3, e000340.	3.7	45
9	Pak1 Is Required to Maintain Ventricular Ca <sup>2+</sup> Homeostasis and Electrophysiological Stability Through SERCA2a Regulation in Mice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 938-948.	4.8	32
10	Inhibition of Angiotensin II-Induced Cardiac Hypertrophy and Associated Ventricular Arrhythmias by a p21 Activated Kinase 1 Bioactive Peptide. <i>PLoS ONE</i> , 2014, 9, e101974.	2.5	23
11	A Novel Immunomodulator, FTY-720 Reverses Existing Cardiac Hypertrophy and Fibrosis From Pressure Overload by Targeting NFAT (Nuclear Factor of Activated T-cells) Signaling and Periostin. <i>Circulation: Heart Failure</i> , 2013, 6, 833-844.	3.9	57
12	Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 702-711.	1.9	31
13	Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 988-996.	1.9	52
14	Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart. <i>Circulation</i> , 2011, 124, 2702-2715.	1.6	106
15	Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H1487-H1495.	3.2	94
16	Cardiac-Specific Deletion of <i>Mkk4</i> Reveals Its Role in Pathological Hypertrophic Remodeling but Not in Physiological Cardiac Growth. <i>Circulation Research</i> , 2009, 104, 905-914.	4.5	67
17	c-Jun N-Terminal Kinase Activation Mediates Downregulation of Connexin43 in Cardiomyocytes. <i>Circulation Research</i> , 2002, 91, 640-647.	4.5	134